Document:

Exhibit

  Exhibit 10.12

Performance Unit Award Agreement
This Performance Unit Award Agreement (this “Agreement”) is made and entered into as of __________ (the “Grant Date”) by and between Team, Inc., a Delaware corporation (the “Company”) and ____________ (the “Grantee”).
WHEREAS, the Company has adopted the Team, Inc. 2018 Equity Incentive Plan (the “Plan”) pursuant to which Restricted Stock Units may be granted; and
WHEREAS, the Committee has determined that it is in the best interests of the Company and its shareholders to grant the award of Restricted Stock Units which become vested based on continued service and the attainment of designated performance goals as provided for herein.
NOW, THEREFORE, the parties hereto, intending to be legally bound, agree as follows:
1.Grant of Performance Units.  Pursuant to Section VI of the Plan, the Company hereby grants to the Grantee an Award of [____] Restricted Stock Units (the “Award”), which shall become vested based on the attainment of the Performance Criteria designated in Section 2 and Exhibit A.  (For purposes of Exhibit A, the number of shares listed in the preceding sentence is the “Target Amount”) Each performance-based Restricted Stock Unit (a “PSU”) represents the right to receive one share of Common Stock, subject to the terms and conditions set forth in this Agreement and the Plan. 
2.    Performance Criteria.  The Award’s performance period (“Performance Period”) and criteria (“Performance Criteria”) are set forth in Exhibit A to this Agreement.  The Performance Criteria have been established by the Committee, which shall determine and certify whether such criteria have been satisfied. 
3.    Determination of Performance.  Following completion of the Performance Period and prior to___________, the Committee will review and certify in writing whether (i) the Performance Criteria have been satisfied, and (ii) the number of PSUs granted under Section 1 shall be increased as provided in Exhibit A.  At that time, the Committee may exercise negative discretion to reduce the number of shares of Common stock to be delivered pursuant to this Agreement.  Following the issuance of this certification, the number of PSUs that the Grantee shall earn, if any, shall be final, conclusive and binding on the Grantee, and on all other persons, to the maximum extent permitted by law.
4.    Vesting of PSUs. The PSUs are subject to forfeiture until they vest. Except as otherwise provided herein, the PSUs will vest and become non-forfeitable on _________, subject to (i) the achievement of the Performance Criteria, (ii) the exercise of the Committee’s discretion to reduce the number of PSUs subject to this Award, and (iii) the Grantee’s “Continuous Service” with the Company from the Grant Date through the date payments are made pursuant to this Agreement, which shall be not later than ________.  

1

5.    Termination of Continuous Service.
5.1    Except as otherwise expressly provided in this Agreement, if the Grantee’s employment with the Company terminates for any reason at any time prior to the date payments are made under this Agreement as provided in Section 4 above, all of the PSUs shall be automatically forfeited upon such termination of Continuous Service and neither the Company nor any Affiliate shall have any further obligations to the Grantee under this Agreement.
5.2    Notwithstanding Section 5.1, if the Grantee’s Continuous Service terminates during the Performance Period as a result of the Grantee’s death or Disability, the Grantee will vest on such date in a portion of the PSUs determined by multiplying (i) the Target Amount, by (ii) a fraction, the numerator of which equals the number of days that the Grantee was employed between _________ and the date of death or Disability, and the denominator of which equals ___. Any remaining PSUs subject to this Agreement shall be forfeited on the date of death or Disability.
6.    Effect of a Change in Control. If there is a Change in Control during the Performance Period, the Grantee shall be vested in the PSUs on the effective date of the Change in Control at the Target Amount, which amount shall be paid no later than thirty (30) days following such Change in Control.  
7.    Payment of PSUs. Payment in respect of the PSUs earned for the Performance Period shall be made in shares of Common Stock and shall be issued to the Grantee as soon as practicable following the vesting date, provided such payment shall be made not later than _______. The Company shall (i) issue and deliver to the Grantee the number of shares of Common Stock equal to the number of vested PSUs less applicable tax withholding, and (ii) enter the Grantee’s name on the books of the Company as the shareholder of record with respect to the shares of Common Stock delivered to the Grantee.
8.    Transferability. Subject to any exceptions set forth in this Agreement or the Plan, the PSUs or the rights relating thereto may not be assigned, alienated, pledged, attached, sold or otherwise transferred or encumbered by the Grantee, except by will or the laws of descent and distribution, and upon any such transfer by will or the laws of descent and distribution, the transferee shall hold such PSUs subject to all of the terms and conditions that were applicable to the Grantee immediately prior to such transfer. 
9.    Rights as Shareholder; Dividend Equivalents.
9.1    The Grantee shall not have any rights of a shareholder with respect to the shares of Common Stock underlying the PSUs, including, but not limited to, voting rights and the right to receive or accrue dividends or dividend equivalents. 
9.2    Upon and following the vesting of the PSUs and the issuance of shares, the Grantee shall be the record owner of the shares of Common Stock underlying the PSUs unless and until such shares are sold or otherwise disposed of, and as record owner shall be 

2

entitled to all rights of a shareholder of the Company (including voting and dividend rights, if any). 
10.    No Right to Continued Service. Neither the Plan nor this Agreement shall confer upon the Grantee any right to be retained in any position, as an Employee, Consultant or Director of the Company. Further, nothing in the Plan or this Agreement shall be construed to limit the discretion of the Company to terminate the Grantee’s Continuous Service at any time, with or without Cause. 
11.    Adjustments. If any change is made to the outstanding Common Stock or the capital structure of the Company, if required, the PSUs shall be adjusted or terminated in any manner as contemplated by Section 20 of the Plan.
12.    Tax Liability and Withholding.
12.1    The Grantee shall be required to pay to the Company, and the Company shall have the right to deduct from any compensation paid to the Grantee pursuant to the Plan, the amount of any required withholding taxes in respect of the PSUs and to take all such other action as the Company deems necessary to satisfy all obligations for the payment of such withholding taxes. As a condition of the receipt of this grant, prior to the vesting of the PSUs Grantee hereby agrees to make such arrangements as the Company may require in order to satisfy any required federal, state, local or foreign withholding tax obligations, calculated using rates of up to, but not exceeding, the maximum statutory withholding rates applicable in the Grantee’s particular jurisdiction, that the Company, in its sole discretion, determines may arise in connection with the receipt of this grant or the issuance of shares of Common Stock (the “Tax Obligations”). Grantee understands that the Company shall not be required to issue any shares of Common Stock under the Plan unless and until such Tax Obligations are satisfied. 
12.2    The Company intends, and Grantee hereby authorizes the Company, to satisfy the Tax Obligations by withholding from the Grantee’s vested PSUs the number of full shares of Common Stock having an aggregate market value at that time of vesting equal to the amount the Company determines are equal to the Tax Obligations, with the remainder to be satisfied by withholding from Grantee’s wages or other cash compensation payable by the Company or your employer. To the extent the Company determines that the number of PSUs or shares of Common Stock withheld pursuant to this Paragraph is insufficient to satisfy such Tax Obligations, Grantee hereby authorizes the Company or Grantee’s employer to deduct from Grantee’s compensation the additional amounts necessary to fully satisfy the Tax Obligations. If the Company chooses not to deduct such amount from Grantee’s compensation, Grantee agrees to pay the Company, in cash or by check, the additional amount necessary to fully satisfy the Tax Obligations. Grantee hereby agrees to take any further actions and execute any additional documents as may be necessary to effectuate the provisions of this Paragraph.
12.3    Notwithstanding any action the Company takes with respect to any or all income tax, social insurance, payroll tax, or other tax-related withholding (“Tax-Related 

3

Items”), the ultimate liability for all Tax-Related Items is and remains the Grantee’s responsibility and the Company (i) makes no representation or undertakings regarding the treatment of any Tax-Related Items in connection with the grant, vesting or settlement of the PSUs or the subsequent sale of any shares, and (ii) does not commit to structure the PSUs to reduce or eliminate the Grantee’s liability for Tax-Related Items.
13.    Compliance with Law. The issuance and transfer of shares of Common Stock in connection with the PSUs shall be subject to compliance by the Company and the Grantee with all applicable requirements of federal and state securities laws and with all applicable requirements of any stock exchange on which the Company’s shares of Common Stock may be listed. No shares of Common Stock shall be issued or transferred unless and until any then applicable requirements of state and federal laws and regulatory agencies have been fully complied with to the satisfaction of the Company and its counsel. 
14.    Notices. Any notice required to be delivered to the Company under this Agreement shall be in writing and addressed to the General Counsel of the Company at the Company’s principal corporate offices. Any notice required to be delivered to the Grantee under this Agreement shall be in writing and addressed to the Grantee at the Grantee’s address as shown in the records of the Company. Either party may designate another address in writing (or by such other method approved by the Company) from time to time.
15.    Governing Law. This Agreement will be construed and interpreted in accordance with the laws of the State of Texas without regard to conflict of law principles.
16.    Interpretation. Any dispute regarding the interpretation of this Agreement shall be submitted by the Grantee or the Company to the Committee for review. The resolution of such dispute by the Committee shall be final and binding on the Grantee and the Company.
17.    PSUs Subject to Plan. This Agreement is subject to the Plan as approved by the Company’s shareholders. The terms and provisions of the Plan, as it may be amended from time to time, are hereby incorporated herein by reference. In the event of a conflict between any term or provision contained herein and a term or provision of the Plan, the applicable terms and provisions of the Plan will govern and prevail.
18.    Successors and Assigns. The Company may assign any of its rights under this Agreement. This Agreement will be binding upon and inure to the benefit of the successors and assigns of the Company. Subject to the restrictions on transfer set forth herein, this Agreement will be binding upon the Grantee and the Grantee’s beneficiaries, executors, administrators and the person(s) to whom the PSUs may be transferred by will or the laws of descent or distribution.
19.    Severability. The invalidity or unenforceability of any provision of the Plan or this Agreement shall not affect the validity or enforceability of any other provision of the Plan or this Agreement, and each provision of the Plan and this Agreement shall be severable and enforceable to the extent permitted by law.

4

20.    Discretionary Nature of Plan. The Plan is discretionary and may be amended, cancelled or terminated by the Company at any time, in its discretion. The grant of the PSUs in this Agreement does not create any contractual right or other right to receive any PSUs or other Awards in the future. Future Awards, if any, will be at the sole discretion of the Company. Any amendment, modification, or termination of the Plan shall not constitute a change or impairment of the terms and conditions of the Grantee’s employment with the Company.
21.    Amendment. The Committee has the right to amend, alter, suspend, discontinue or cancel the PSUs, prospectively or retroactively; provided, that, no such amendment shall adversely affect the Grantee’s material rights under this Agreement without the Grantee’s consent. 
22.     Clawback.  Notwithstanding any provisions in the Agreement to the contrary, any compensation, payments, or benefits provided hereunder (or profits realized from the sale of the Common Stock delivered hereunder), whether in the form of cash or otherwise, shall be subject to a clawback (i) to the extent necessary to comply with the requirements of any applicable law, including but not limited to, the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, section 304 of the Sarbanes Oxley Act of 2002 or any regulations promulgated thereunder; or (ii) to the extent provided by the Team, Inc. Incentive Compensation Clawback Policy, any other policy or procedure adopted by the Company or any individual agreement between Employee and the Company.
23.    Section 409A. This Agreement is intended to comply with Section 409A of the Code or an exemption thereunder and shall be construed and interpreted in a manner that is consistent with the requirements for avoiding additional taxes or penalties under Section 409A of the Code. Notwithstanding the foregoing, the Company makes no representations that the payments and benefits provided under this Agreement comply with Section 409A of the Code and in no event shall the Company be liable for all or any portion of any taxes, penalties, interest or other expenses that may be incurred by the Grantee on account of non-compliance with Section 409A of the Code. 
24.    No Impact on Other Benefits. The value of the Grantee’s PSUs is not part of his or her normal or expected compensation for purposes of calculating any severance, retirement, welfare, insurance or similar employee benefit.
25.    Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an original but all of which together will constitute one and the same instrument. Counterpart signature pages to this Agreement transmitted by facsimile transmission, by electronic mail in portable document format (.pdf), or by any other electronic means intended to preserve the original graphic and pictorial appearance of a document, will have the same effect as physical delivery of the paper document bearing an original signature.
26.    Acceptance. The Grantee hereby acknowledges receipt of a copy of the Plan and this Agreement. The Grantee has read and understands the terms and provisions thereof, and accepts the PSUs subject to all of the terms and conditions of the Plan and this Agreement. The Grantee acknowledges that there may be adverse tax consequences upon the vesting or settlement of the PSUs or disposition of the underlying shares and that the Grantee has been advised to consult a tax advisor prior to such vesting, settlement or disposition.

5

27.    IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first above written.

	
		
	 
	TEAM, INC.

	 
	By: ______________________________
Name: ____________________________
Title:  ____________________________ 

	 
	 

	 
	GRANTEE
By: ______________________________
Printed Name: ______________________
Date Signed: _______________________

6

EXHIBIT A

Performance Period and Performance Criteria

7EX-10.9.1

 Exhibit 10.9.1 

CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND MARKED WITH “[***]”. AN
UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 
 ATTACHMENT A 

PROJECT RIDER #2 
 This Rider #2
(“Rider”) is issued pursuant to the Collaboration Agreement (“Agreement”), effective November 10, 2017, between Magenta Therapeutics (“Magenta”) and Be The Match BioTherapies, LLC
(“BTMB”) and incorporates all of the terms and conditions therein. The effective date of this Rider shall be the date of the final signature executing this Rider. 

POINT OF CONTACT 
 Be The
Match BioTherapies - 500 N 5th St.. Minneapolis. MN 55401 
  

	 	•	 	 Contact: [***] 

  

	 	•	 	 Phone:   [***] 

 

	 	•	 	 E-mail:  [***] 

Magenta Therapeutics - 50 Hampshire St. Cambridge. MA 02139 
  

	 	•	 	 Contact: [***] 

  

	 	•	 	 Phone:   [***] 

 

	 	•	 	 E-mail:  [***] 

BTMB and Magenta (each a “Party” and collectively the “Parties”) agree as follows: 

 

	A.	 STATEMENT OF WORK. 

BTMB will provide the following services: 

SET UP AND MOCK SHIPMENT 

BTMB will build an upfront set-up process customized to Magenta’s specifications, including
creating a logistics plan, and providing training to the manufacturer, and transplant sites. BTMB will also provide the planning and facilitation of a shipment of mock manufactured product, e.g. saline, from Magenta selected manufacturing facility
to Magenta identified site, as listed in Exhibit A. Planning and facilitation includes coordinating shipping with the manufacturer and transplant site, supplying sample documentation to be used with the mock shipment, and providing detailed
oversight of the project to achieve shipping specifications, Magenta will supply mock product and product configuration to be loaded into the LN2 shippers. A report of the mock shipment results will be provided to Magenta by BTMB. These
shipments will help confirm that the manufacturing facility is capable of handling and packaging materials for safe shipment. 
 Shipment
will use mutually agreeable service provider (e.g., Cryoport, World Courier) and be managed via BTMB processes, using qualified, charged LN2 vapor shippers and digital temperature trackers. BTMB will provide Magenta records and temperature transport
data. 

  
 Page 1 of 5 

Services Agreement 

 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS
OMITTED AND MARKED WITH “[***]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

 RESEARCH PRODUCT SHIPMENT 

BTMB will plan, facilitate and provide Case Management and Logistics support of a shipment of research manufactured product, e.g. cells, from
Magenta selected manufacturing facility to Magenta identified site, as listed in Exhibit A. Magenta will supply research product and product configuration to be loaded into the LN2 shippers. All shipment documentation will be provided by
Magenta or by its selected manufacturer. 
 Shipment will use mutually agreeable service provider (e.g., Cryoport, World Courier) and be
managed via BTMB processes, using qualified, charged LN2 vapor shippers and digital temperature trackers. BTMB will provide Magenta records and temperature transport data. 
  

	B.	 PROJECT CHANGES. 

The Parties understand that in order to reflect changes to this Rider, the Rider will be subject to amendment by the Parties. Each party’s
respective Point Of Contact identified above may request or submit a written request for change to the other party’s Point of Contact. The request for change should describe in appropriate detail the nature, extent and proposed manner of
performance of the proposed change, related implications (if any) arising there from and estimated scheduling, pricing and cost information relating thereto. Written approval or rejection of the requested change will be provided within [***] from
the date of receipt. 
  

	C.	 COMPENSATION OF BTMB. 

BTMB shall be compensated in exchange for the provision of services in accordance with the terms of the Agreement in accordance with the
Payment Schedule set forth below. All amounts due under this Payment Schedule will be invoiced in United States Dollars as follows: 
  

	 	1.	 Payment Schedule 

 

	 	1.1	 Set up and Initial Mock Shipment 

Magenta agrees to pay BTMB $[***] ([***] dollars) to provide upfront set-up, planning and facilitation
of the mock shipment from the manufacturing facility to the identified site and provide a report. 
  

	 	1.2	 Ongoing Shipments 

Magenta agrees to pay BTMB $[***] ([***] dollars) to plan, facilitate and provide Case Management and Logistics support of the ongoing
shipment from the manufacturing facility to the identified site. 
  

	 	1.3	 Logistics Costs 

Magenta agrees to pay all actual shipping fees (billed at cost) associated with each mock and ongoing shipments of product. BTMB will not mark
up these fees and will work to secure the best possible pricing for Magenta while maintaining the needed compliance and chain of custody requirements. 

  
 Page 2 of 5 

Services Agreement 

 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS
OMITTED AND MARKED WITH “[***]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

	 	2.	 Travel 

Any travel by BTMB personnel under this Rider shall be approved in writing in advance by Magenta. All travel and any reasonable expenses
associated with pre-approved travel will be reimbursed by Magenta in accordance with the applicable BTMB travel policies and procedures in effect at such time as the travel and/or travel expenses are incurred
by BTMB. BTMB will use its own designated travel agency to book pre-approved travel. 
 Travel
expenses incurred will be categorized as “Travel” on BTMB invoices and will be appropriately described. 
  

	 	3.	 Invoice. 

BTMB may use its own invoice format referencing this Rider or Purchase Order assigned. All BTMB invoices shall be sent to the Magenta Point of
Contact provided at the address listed above or via email to Magenta Accounting at [***]. 
 All duly issued invoices are due and payable
within [***] from invoice date in currency USD. Invoice number must be included with payment. 
 For automated clearing house (ACH) remit
funds (free of all bank fees) to: 
 [***] 

Magenta is not required to pay any amounts, costs or expenses, except as expressly set forth in this Section (C). 

 

	D.	 TERM. The term of this Rider shall commence on the Rider effective date set forth
above and continue and remain in effect through [***] from the Rider effective date. 

  

	E.	 TERMINATION OF RIDER. 

Upon the effective date of any termination, BTMB shall immediately cease performance of its Services. Magenta agrees to pay BTMB for all
services performed through the effective date of termination. 
 This Rider must be signed by individuals authorized to legally bind their
respective Parties. 
 [Signature Page Follows] 

  
 Page 3 of 5 

Services Agreement 

 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS
OMITTED AND MARKED WITH “[***]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

									
	BE THE MATCH BIOTHERAPIES, LLC	 	MAGENTA THERAPEUTICS
					
	By: 	 	/s/ Brian Lindberg	 		 	By:	 	/s/ Karen M. Nichols
		 	Authorized Signature	 		 		 	Authorized Signature
					
		 	Brian Lindberg	 		 		 	Karen M. Nichols
		 	(Typed/Printed Name)	 		 		 	(Typed/Printed Name)
					
	Title:	 	Corporate Vice President	 		 	Title:	 	VP, Regulatory and Quality
					
	Date:	 	Jun 22, 2018	 		 	Date:	 	26 Jun 2018

  
 Page 4 of 5 

Services Agreement 

 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS
OMITTED AND MARKED WITH “[***]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

 EXHIBIT A 

SITE(S) 
 Manufacturer 

University of MN—Minneapolis, MN 
 Transplant
Centers  
 Duke University—Durham, NC 

Emory University—Atlanta, GA 
 Cincinnati
Children’s Hospital—Cincinnati, OH 

  
 Page 5 of 5 

Services Agreement

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00293-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00293-of-00352.parquet"}]]